Sarepta Therapeutics has announced a strategic restructuring plan designed to prioritise high-value, high impact programmes, and support its long-term financial viability.   This plan includes a 36% workforce reduction, impacting approximately 500 employees, and an emphasis on near- and mid-term opportunities from the siRNA platform.  Several programmes, including most of the gene therapies in development for […]